On 01 April 2020, the FAMHP took a certain number of measures to avoid drug shortages during the coronavirus pandemic (COVID-19). These measures were refined in the consolidated version (link is external) of the Administrator General of the FAMHP's decision relating to various urgent measures concerning specific drugs to combat the drug shortage during the SARS-CoV-2 pandemic.
Replacing the ban on exports outside the EEA with a notification requirement with the possibility of opposition
In order to prevent other countries from suffering unnecessary drug shortages, the ban on exports outside the EEA has been replaced by a notification requirement. The FAMHP can still file an opposition, within three working days, if this is in the interest of Belgian patients, in which case the medicinal products cannot be exported.
Instructions regarding the notification requirement:
Revision of the list of medicinal products
The list of medicinal products and raw materials concerned has also been revised. For example, for the sake of clarity, IVs (form of medication suitable for intravenous administration and important in the treatment of patients with COVID-19) have been added if necessary. The situation is constantly evolving, and the list has also been adapted accordingly.
To read more Press Release articles, click here.